Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Fudan University

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: Pertuzumab Plus Trastuzumab; Drug: Pyrotinib Plus Trastuzumab

Study type: Observational

Funder types: Other

Identifiers

NCT05572645

YOUNGBC-21

Details and patient eligibility

About

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Full description

This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in patients with HER2-positive metastatic breast cancer.

Enrollment: 333 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.
• Patients received Pyrotinib(320-400 mg, po, qd) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) or Pertuzumab(840mg q3w, and then 420 mg q3w) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) for at least one cycle, starting from Jan 2018 to Sep 2022.
• Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.

Exclusion criteria

• Incomplete medical history

Trial design

333 participants in 2 patient groups

PyroH

Description:

treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)

Treatment:

Drug: Pyrotinib Plus Trastuzumab

PertH

Description:

treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)

Treatment:

Drug: Pertuzumab Plus Trastuzumab